CEGEPHAR

Active

Private limited companyfounded 1993active for 33 yearsRue Emile Vandervelde 30, 4624 Fléron, BelgiumKBO/BCE: BE 0450.412.570

Summary

CEGEPHAR has been active since 1993 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €200,669 and a net result of €108,204. Equity is growing by about 31% per year across the filed financial years. Its solvency ranks better than 37% of 12,672 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.4% (very low).

Risk analysisFollow Report Compare

CEGEPHARActiveChecked score 85/100

Risk analysis Report Compare

Activity

Retail sale of pharmaceutical products

NACE 47730

10th oldest company in Fléron, Wholesale and retail trade sector1 site

Size

€787,032total assets 2025

Staff: 4.4 FTE
Equity: €200,669
Profit: €108,204

Financial health

85 Excellent Checked score 2025

Bankruptcy probabilitywithin 12 months: 0.4%

Structure

Parent: PHARMACIE FONZE · 97.15%

2025 accounts 21 days early1 deed in the Belgian Official Gazette

Why 85raises riskSector: Retail trade (NACE 47)Equity €200,669 (25.5% of total assets)Liquidity: current ratio 0.90, cash €39,395lowers riskFounded in 1993Show the evidence

Checked score

Score 2025

85 / 100

Excellent

Probability in this band: under 0.55%

Financially better than 56% of its sector peers (NACE 47, micro)

Every signal that counts is listed under Signals.

Financial strength · tick = 2024

Average

Solvency 50+7

equity 25.5% of total assets

Liquidity 27-3

short-term debt 57.4% · cash 5.0%

Profitability 86+4

return on assets 13.7%

Bankruptcy probability, 12 months

0.4% Very low

0%0.5%1.5%4%10%≥ 25%

About 4 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.6% (40,231 companies, NACE 47, micro)

Last 24 months 11-2024: 0.5% 12-2024: 0.5%● unchanged vs 11-2024 01-2025: 0.5%● unchanged vs 12-2024 02-2025: 0.5%● unchanged vs 01-2025 03-2025: 0.5%● unchanged vs 02-2025 04-2025: 0.5%● unchanged vs 03-2025 05-2025: 0.5%● unchanged vs 04-2025 06-2025: 0.6%▲ +0.1 percentage points vs 05-2025highest value 07-2025: 0.5%▼ -0.1 percentage points vs 06-2025 08-2025: 0.5%● unchanged vs 07-2025 09-2025: 0.5%● unchanged vs 08-2025 10-2025: 0.5%● unchanged vs 09-2025 11-2025: 0.5%● unchanged vs 10-2025 12-2025: 0.5%● unchanged vs 11-2025 01-2026: 0.5%● unchanged vs 12-2025 02-2026: 0.5%● unchanged vs 01-2026 03-2026: 0.5%● unchanged vs 02-2026 04-2026: 0.5%● unchanged vs 03-2026 05-2026: 0.5%● unchanged vs 04-2026 06-2026: 0.5%● unchanged vs 05-2026 07-2026: 0.6%▲ +0.1 percentage points vs 06-2026 08-2026: 0.4%▼ -0.2 percentage points vs 07-2026 09-2026: 0.4%● unchanged vs 08-2026 10-2026: 0.4%● unchanged vs 09-2026lowest value

Credit of up to €17,000 on 30-day terms is acceptable

Liquidity insufficient (current ratio 0.9, compared with 0.85 in 2024, below 1; short-term debt: 57.4% and cash: 5% of total assets), and 74.5% of the assets are financed with debt and provisions.

How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100	Excellent	under 0.55%
60-74	Healthy	0.55% to 1.5%
45-59	Fair	1.5% to 4.2%
25-44	Weak	4.2% to 15.0%
0-24	Critical	over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro): better than 41% on solvency, 24% on liquidity, 80% on profitability and 80% on growth.

The bankruptcy probability was computed on 24-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.

lowers riskraises riskneutral

Sector: Retail trade (NACE 47)

KBO

Founded in 1993

Companies that have existed this long fail less often; how much that weighs depends on the rest of its profile.

KBO

Equity €200,669 (25.5% of total assets)

NBB · annual accounts

Liquidity: current ratio 0.90, cash €39,395

NBB · annual accounts

Latest accounts filed on time

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 10-07-2026, 21 days ahead of the deadline.

NBB · 10 filings

Deviation from the deadline

2025

21 days early

2024

42 days early

2023

47 days early

2022

5 days early

2021

59 days early

2020

15 days early

2019

10 days late

← before the deadline after the deadline →

tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 26 days before the deadline; the sector median (NACE 47) for financial year 2024 is on the deadline day, and 47% of those companies filed late.

Searched, nothing found (2)

Next filing not due yet

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 19 June (4 of the last 5 filed years within 30 days of that day).

Companies Code · seven months

Where today falls in the filing period

25-10-2026 today31-12-2026 year end31-07-2027 deadline

No strike-offs in the KBO publications

Searched since 2021.

KBO publications · our coverage

10-07-2026 Annual accounts filedfinancial year 2025 · abbreviated…
31-12-2025 Highest result from 2018 to 2025net €108,204 ▲26%
31-12-2025 Equity above €200,000equity €200,669 ▲31.6%

Key points

Positive: 10th oldest company in Fléron, Wholesale and retail trade sectorin the Checked rankings No. 10 View
Controlled by PHARMACIE FONZE 97.15% View
Positive: Filed on time since financial year 2020accounts within the deadline every year 6 years View
Positive: 5 profitable years in a rowprofit 2025: €108,204 5 years View

By topic

Financials

Financial year: 2025
Total assets: €787,032
Profit: €108,204
Solvency: 25.5%

Total assets▼ 5.9%

Net result

20182025

Go to Financials

Board & ownership

Parent: PHARMACIE FONZE · 97.15%

Go to Board & ownership

Timeline

Events: 38
Since: 1995
Next accounts: by 31-07-2027

19-06-2025Annual accounts filed
31-12-2024Equity above €150,000
14-06-2024Annual accounts filed

Go to Timeline

Company details

Sites: 1

Legal form: Private limited company
Activity: Retail sale of pharmaceutical productsNACE 47730
Founded: 16-06-1993
Year ends: 31-12
Peppol: Reachable for e-invoices

Go to Company details

Key facts about CEGEPHAR

What is the company number of CEGEPHAR?: 0450.412.570. In Belgium the VAT number is the company number with BE in front: BE 0450.412.570.
Where is CEGEPHAR based?: The registered office is at Rue Emile Vandervelde 30, 4624 Fléron.Company details
What does CEGEPHAR do?: According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of CEGEPHAR?: Private limited company (BV).
When was CEGEPHAR founded?: On 16-06-1993.
Is CEGEPHAR still active?: Yes, CEGEPHAR is an active enterprise in the KBO register.
How many employees does CEGEPHAR have?: On average 4.4 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of CEGEPHAR?: Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.
Is CEGEPHAR profitable?: In financial year 2025, CEGEPHAR made a profit of €108,204.
Where can I find the annual accounts of CEGEPHAR?: CEGEPHAR filed 32 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of CEGEPHAR due?: By 31-07-2027, for financial year 2026.Timeline